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ABSTRACT: Charcot-Marie-Tooth (CMT) disease com-
prises a heterogeneous group of peripheral neuropathies
characterized by muscle weakness and wasting, and im-
paired sensation in the extremities. Four genes encoding
an aminoacyl-tRNA synthetase (ARS) have been impli-
cated in CMT disease. ARSs are ubiquitously expressed,
essential enzymes that ligate amino acids to cognate tRNA
molecules. Recently, a p.Arg329His variant in the alanyl-
tRNA synthetase (AARS) gene was found to segregate
with dominant axonal CMT type 2N (CMT2N) in two
French families; however, the functional consequence of
this mutation has not been determined. To investigate
the role of AARS in CMT, we performed a mutation
screen of the AARS gene in patients with peripheral neu-
ropathy. Our results showed that p.Arg329His AARS
also segregated with CMT disease in a large Australian
family. Aminoacylation and yeast viability assays showed
that p.Arg329His AARS severely reduces enzyme activ-
ity. Genotyping analysis indicated that this mutation arose
on three distinct haplotypes, and the results of bisulfite
sequencing suggested that methylation-mediated deamina-
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tion of a CpG dinucleotide gives rise to the recurrent
p.Arg329His AARS mutation. Together, our data suggest
that impaired tRNA charging plays a role in the molecular
pathology of CMT2N, and that patients with CMT should
be directly tested for the p.Arg329His AARS mutation.
Hum Mutat 33:244–253, 2012. C© 2011 Wiley Periodicals, Inc.
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Introduction
Charcot-Marie-Tooth (CMT) disease is a clinically and geneti-
cally heterogeneous disorder of the peripheral nerve characterized
by distal symmetric polyneuropathy (DSP) [England et al., 2009a,
b], muscle weakness and wasting, diminished deep tendon reflexes,
impaired sensation in the extremities, pes cavus, and steppage gait
[Dyck and Lambert, 1968; Murakami et al., 1996]. CMT disease
is a frequent cause of inherited peripheral neuropathy with an esti-
mated frequency of one in 2,500 individuals worldwide [Skre, 1974].
According to electrophysiological criteria, CMT disease is divided
into three major subtypes [Dyck and Lambert, 1968; Nicholson
and Myers, 2006]. In CMT1, patients exhibit defects in myelinat-
ing Schwann cells that lead to reduced motor nerve conduction
velocities (MNCVs). In CMT2, MNCV values are normal and pa-
tients exhibit axonal loss accompanied by decreased amplitudes in
evoked motor nerve responses. Finally, intermediate CMT is con-
sidered when individual families contain both patients with normal
MNCVs and those with reduced MNCVs [Nicholson and Myers,
2006].
Mutations in four genes encoding an aminoacyl-tRNA syn-
thetase (ARS) have been implicated in CMT disease with an axonal
C© 2011 WILEY PERIODICALS, INC.
pathogenesis: glycyl-tRNA synthetase (GARS; MIM# 600287) in
CMT type 2D (CMT2D; MIM# 601472), tyrosyl-tRNA synthetase
(YARS; MIM# 603623) in dominant intermediate CMT type C
(CMTDIC; MIM# 608323), alanyl-tRNA synthetase (AARS; MIM#
601065) inCMT type 2N (CMT2N;MIM# 613287), and lysyl-tRNA
synthetase (KARS; MIM# 601421) in CMT intermediate recessive
type B (CMTRIB;MIM# 613641) [Antonellis et al., 2003; Jordanova
et al., 2006; Latour et al., 2010; McLaughlin et al., 2010]. ARSs are
ubiquitously expressed, essential enzymes that attach amino acids
to their cognate tRNA molecules in the cytoplasm and mitochon-
dria, thus completing the first essential step of protein translation
[Antonellis and Green, 2008]. The extent of involvement of ARS
genes in CMT and the exact pathogenic mechanism by which ARS
mutations lead to peripheral neuropathy remains unclear.
In a recent study, a single AARS mutation (p.Arg329His) was
found to segregate with dominant CMT disease in two French fam-
ilies, and haplotype analysis excluded a founder effect [Latour et al.,
2010]. Interestingly, mutagenesis of the analogous amino acid in
E. coli (p.Arg314Ala alaS) resulted in a approximately 700-fold re-
duction in aminoacylation activity [Ribas de Pouplana et al., 1998].
However, histidine was not tested at this amino acid position, and
the human p.Arg329His mutation has not been functionally evalu-
ated. Furthermore, the prevalence andmutagenicmechanism of the
p.Arg329His AARSmutation remain unknown. Here, we show that
p.Arg329His AARS represents a recurrent, loss-of-function muta-
tion that arises due to methylation-mediated deamination of a CpG
dinucleotide.
Materials and Methods
ARS Mutation Screen
DNA samples were isolated from 363 patients diagnosed with
peripheral neuropathy by collaborating physicians. DNA samples
from the ClinSeqTM cohort were collected as previously described
[Biesecker et al., 2009]. The appropriate review boards of each par-
ticipating institution approved these studies. The AARS gene was
assessed for mutations at the NIH Intramural Sequencing Center
(NISC) as previously described [McLaughlin et al., 2010]. Each
AARS variant was independently confirmed via PCR amplifica-
tion followed by DNA sequencing analysis. Nucleotide positions
are relative to the open reading frame from GenBank Accession No.
NM_001605.2. Nucleotide numbering reflects cDNA position with
+1 corresponding to the A of the ATG translation initiation codon
in the reference sequence. Codon numbering for the AARS protein
was based on the reported amino acid sequence (NCBI accession
no. NP_001596.2). The initiation codon is codon 1.
National Institute of Neurological Disease (NINDS)
Control Genotyping
A total of 576 DNA samples isolated from neurologically nor-
mal controls were obtained from the National Institute of Neu-
rological Disease (NINDS) and Coriell Institute for Medical Re-
search (PanelnumbersNDPT079,NDPT082,NDPT084,NDPT090,
NDPT093, and NDPT094) and genotyped for each AARS vari-
ant using MassARRAY R© iPLEX Gold technology (Sequenom, San
Diego, CA). Briefly, multiplex locus-specific PCR reactions were
performed (primer sequences available upon request) followed by
primer extension assays using mass-modified dideoxynucleotide
terminators. MALDI-TOF mass spectrometry was used to deter-
mine the genotype for each individual using SpectroTYPERsoftware
(Sequenom).
Comparative Sequence Analysis
To perform comparative protein sequence analysis, we first em-
ployed the NCBI BLAST tool (http://blast.ncbi.nlm.nih.gov/Blast
.cgi) to collect AARS protein orthologs from the indicated
species. Multiple-species amino acid sequence alignments were
then generated using Clustal W2 software [Larkin et al., 2007]
and the following accession numbers: human (Homo sapiens,
NP_001596.2), chimpanzee (Pan troglodytes, XP_001169474.1),
mouse (Mus musculus, NP_666329.2), frog (Xenopus laevis,
NP_001121342.1), zebrafish (Danio rerio, NP_001037775.1), fruit
fly (Drosophila melanogaster, NP_523511.2), baker’s yeast (Saccha-
romyces cerevisiae, NP_014980.1), and bacteria (Escherichia coli
IAI39, YP_002408816.1).
AARS and ALA1 Expression Constructs
DNA constructs for aminoacylation and yeast complementation
assays were generated using Gateway cloning technology (Invitro-
gen, Carlsbad, CA). The human AARS open reading frame and the
S. cerevisiae ALA1 locus (including the open reading frame and
630 base pairs (bps) of proximal promoter sequence) were PCR
amplified using human cDNA and S. cerevisiae genomic DNA, re-
spectively. Each primer was designed to include flanking Gateway
attB1 (forward) and attB2 (reverse) sequences (primers for both
genes available upon request). Subsequently, purified PCR products
containing each gene were recombined into the pDONR221 vector
(according to the manufacturer’s instructions) to yield appropriate
entry clones; the insert of each selected entry clone was sequenced
to identify a clone containing each allele with no PCR-induced mu-
tations. Mutagenesis of AARS and ALA1 was performed using the
QuikChange II XL Site-DirectedMutagenesis Kit (Stratagene, Santa
Clara, CA) and appropriate mutation-bearing oligonucleotides.
Subsequently, plasmid DNA purified from each entry clone was
recombined with either a Gateway-compatible pSMT3 destination
vector (for aminoacylation assays), a gateway-compatible DsRed
vector (for localization studies), or a gateway-compatible pRS315
or pRS316 destination vector (for yeast complementation assays)
according to themanufacturer’s instructions. Each resulting expres-
sion construct was analyzed by restriction enzyme digestion with
BsrGI (New England Biosystems, Ipswich,MA) to confirm the pres-
ence of an appropriately sized insert.
Cell Culture and Differentiation
The mouse motor neuron cell line MN-1 [Salazar-Grueso et al.,
1991] was cultured in DMEM growthmedium (Invitrogen) supple-
mented with 10% fetal bovine serum, 100 U/ml penicillin, 50μg/ml
streptomycin, and 2mM L-glutamine, and grown at 37◦C in 5%
CO2. For cell differentiation, transfection studies, and antibody
staining, cultured cells were counted using the Countess Automated
Cell Counter (Invitrogen) and approximately 1.25 × 105 cells were
placed into eachwell of a four-well polystyrene tissue culture treated
glass slide (BD Biosciences, Bedford, MA). MN-1 cells were differ-
entiated by the addition of 2 nM glial cell line-derived neurotrophic
factor (GDNF) and 833 pM GDNF receptor α-1 (GFR α-1; both
from R&D Systems, Minneapolis, MN) to the culture medium and
incubation for 48 hr [Paratcha et al., 2001].
Antibody Staining
Mouse MN-1 cells were cultured at 37◦C for 48 hr in differentia-
tionmedium (see above). Cells were fixed in 4% paraformaldehyde,
permeabilized in 0.2% Triton X-100 in 1× PBS for 5 min, washed
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in 1× PBS, and incubated in blocking solution containing 10%
normal goat serum in 1× PBS with 0.1% sodium azide (Invitro-
gen) for 30 min. Cells were then incubated in 10 μg/ml anti-AlaRS
(B23) (sc-130683, Santa Cruz Biotechnology Inc., Santa Cruz, CA)
in blocking solution for 60 min. After three washes in 1× PBS, cells
were incubated in 1:200 Alexa Fluor 488 goat anti-rabbit IgG (In-
vitrogen) for 60 min. Cells were washed three times in 1× PBS, the
well apparatus was removed, and slides were coated with ProLong
anti-fade reagent (Invitrogen), covered, and sealed. All incubation
and wash steps were performed at room temperature.
MN-1 Transfection Studies
Constructs expressing either wild-type or mutant AARS tagged
with DsRed (described above) were transfected into MN-1 cells
using Lipofectamine 2000 reagent (Invitrogen). For each transfec-
tion reaction, 6 μl of Lipofectamine 2000 and 250 μl of OptiMEM
I minimal growth medium (Invitrogen) were combined and in-
cubated at room temperature for 10 min. Purified plasmid DNA
(4 μg) was diluted in 500 μl of OptiMEM I, combined with the
above Lipofectamine–OptiMEM I mixture, and incubated at room
temperature for 20 min. The entire transfection cocktail was then
added to approximately 1.25 × 105 MN-1 cells in a 15-ml conical
tube. After 2 hr incubation at 37◦C, the transfection reaction was
centrifuged at 2,000 rpm for 2 min and the cells were resuspended
in 250 μl normal growth medium (see above) and allowed to re-
cover for 24 hr at 37◦C. Cells were then washed with 1× PBS and
subsequently incubated with differentiation medium (see above).
After 48 hr, cells were fixed as described above.
Microscopy and Image Analysis
Microscopic images were obtained using the Olympus FluoView
FV500/IX Laser Scanning Confocal Microscope (Olympus, Center
Valley, PA)usingOlympusFluoview image software at theUniversity
of Michigan Microscopy and Image Analysis Core.
AARS Aminoacylation Assays
Wild-type and all mutant enzymes of human AARS were con-
structed with the SMT3 protein fused to the N-terminus to im-
prove solubility for expression in E. coli [Mossessova and Lima,
2000]. Control experiments showed that the presence of the SMT3
protein has no effect on the aminoacylation activity of these en-
zymes. Wild-type and mutant enzymes of human AARS were also
expressed with a His-tag in the C-terminus to allow for affinity pu-
rification through a metal resin. Protein expression was achieved
in E. coli strain Rosetta 2 (DE3) pLysS and purification with the
nickel affinity resin was achieved according to the manufacturer’s
protocol (Novagen, Rockland, MA). The T7 transcript of human
tRNAAla was prepared and purified as previously described [Hou
et al., 1993], and was heat denatured at 85◦C for 3 min and an-
nealed at 37◦C for 20 min before use. Steady-state aminoacylation
assays were monitored at 37◦C in 50 mM HEPES (pH 7.5), 20 mM
KCl, 10 mM MgCl2, 4 mM DTT, 2 mM ATP, and 50 μM ala-
nine with a trace of [3H]-alanine (Perkin Elmer, Waltham, MA)
at a specific activity of 3,693 dpm/pmole. The reaction was ini-
tiated by mixing an AARS enzyme (20–600 nM) with varying
concentrations of tRNA (0.3–20 μM). Aliquots of a reaction mix-
ture were spotted on filter papers, quenched by 5% trichloroacetic
acid (TCA), washed, and measured for radioactivity by a liquid
scintillation counter (Beckman Coulter Inc., Fullerton, CA
LS6000SC). The amount of radioactivity retained on filter pads was
corrected for quenching effects to reveal the amount of synthesis
of Ala-tRNAAla. Steady-state kinetics was determined by fitting the
initial rate of aminoacylation as a function of tRNA concentration
to the Michaelis–Menten equation.
AARS Editing Assays
The substrate Ser-tRNAAla for analysis of post-transfer editing
was prepared by 32P-labeling of the A76 nucleotide in the transcript
of human tRNAAla with the CCA enzyme [Shitivelband and Hou,
2005], followed by aminoacylation with chemically synthesized Ser-
DBE, using the dFx flexizyme [Murakami et al., 2006]. Deacylation
assays were performed at 50 mM HEPES (pH 7.5), 20 mM KCl,
4 mM DTT, and 10 mM MgCl2 at 37◦C, using 5 nM of an AARS
enzyme and 20 μM of Ser-tRNAAla. At the indicated time points,
aliquots of a deacylation reaction were removed and mixed with
S1 nuclease for 30 min to digest the tRNA in the aliquots to 5′-
phosphate mononucleotide. The aliquots were then run on a thin
layer chromatography (TLC) in 0.55 M acetic acid/0.1 M NH4Cl
for 30 min to separate [32P]-seryl-AMP from [32P]-AMP. Quan-
tification of the two products by a phosphorimager and analysis
of the ratio of (Ser-AMP) versus (AMP) determined the extent of
Ser-tRNAAla remained after the editing reaction.
Yeast Viability Assays
A commercially available diploid heterozygous ala1 yeast
strain (MATa/α, his31/his31, leu20/leu20, LYS2/lys20,
met150/MET15, ura30/ura30; Open Biosystems, Hunstville,
AL) was transformed with aURA3-bearing pRS316 vector contain-
ing wild-type ALA1 (see above). Lithium acetate transformations
were performed at 30◦C using 200 ng of plasmid DNA, as pre-
viously described [Green et al., 1999]. Transformation reactions
were grown on yeast medium lacking uracil. Subsequently, sporu-
lation and tetrad dissections were performed to obtain a haploid
ala1 strain that also contains the wild-type ALA1 pRS316 main-
tenance vector. Briefly, the transformed diploid ala1 strain was
patched twice onto presporulation plates (5% D-glucose [Fisher
Scientific, Hampton, NH], 3% nutrient broth [Becton, Dickinson
and Company, Franklin Lakes, NJ], 1% yeast extract [Acros Organ-
ics, Waltham, MA], and 2% agar [Teknova, Hollister, CA]). One
microliter of cells was then transferred into 2 ml of supplemented
liquid sporulation medium (1% potassium acetate [Fisher Scien-
tific], 0.005% zinc acetate [Fisher Scientific], 1× ura supplement
[MP Biomedicals, Solon, OH], 1× his supplement [MP Biomedi-
cals], and 1× leu supplement [MP Biomedicals]) and incubated for
5 days at 25◦C followed by 3 days at 30◦C. Sporulated strains were
dissected using a MSM 400 dissection microscope (Singer Instru-
ments, Somerset, UK), and plated on yeast extract, peptone, and
dextrose (YPD) plates (Becton, Dickinson and Company).
Resulting spores were individually patched onto solid growth
medium containing Geneticin (G418) or 0.1% 5-fluoroorotic acid
(5-FOA), or media lacking uracil (Teknova). Two spores that grew
on G418 and yeast medium lacking uracil, yet did not grow on 5-
FOAmedium, were selected for use in the yeast viability assays. Two
resulting haploid ala1 strains bearing a wild-type ALA1 pRS316
maintenance vector were then transformed with LEU2-containing
pRS315 constructs containingwild-type ormutantALA1 (described
above) and grown onmedium lacking uracil and leucine (Teknova).
For each transformation, five colonies were selected for additional
analysis. Each colony was diluted in 100 μl H2O, then further
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diluted 1:10 and spotted on growthmediumcontaining 0.1%5-FOA
(Teknova), incubated for 3 days at 30◦C, and growth was assessed
by visual inspection. Because 5-FOA is toxic to yeast cells bearing a
functional URA3 allele, only cells that lost the URA3 maintenance
plasmid and for which the LEU2 test plasmid could complement
the chromosomal ala1 allele were expected to grow.
Haplotype Analysis
Microsatellite markers D16S3050, D16S397, and D16S3106 were
genotyped inCMT243 and threeCentre d’Etude duPolymorphisme
Humain (CEPH) Controls: 102-1, 1331-1, and 1332-1 (Coriell,
Camden, NJ). Primer information for these markers was obtained
from the UCSC Genome Browser. The forward primers were 5′ la-
beled with the 6-FAM fluorochrome. Microsatellite markers were
amplified using touchdown PCR protocols in 10-ul reactions con-
taining 10 ng DNA, 1× Immomix (Bioline, Tauton, MA), 8 pmol
primer, and 1× PCR enhancer (Invitrogen). The markers were sent
to the AustralianCancer Research Foundation (ACRF) Facility, Gar-
van Institute of Medical Research (New South Wales, Australia)
for size fractionation using the GeneScan LIZ 600 size standard.
Genotypes were analyzed using GeneMarker version 5.1 software
(SoftGenetics LLC, State College, PA).
CpG Dinucleotide Evaluation and Sodium
Bisulfite Sequencing
The CpG dinucleotide content of the AARS locus (GenBank ac-
cession number NM_001605.2) was evaluated using EMBOSS CpG
Plot (http://www.ebi.ac.uk/Tools/emboss/cpgplot/) [Rice et al.,
2000] using the following criteria: Observed/Expected ratio >
0.60, percent G + percent C > 50.00, and Length > 100. Two
genomic DNA samples from unaffected individuals were treated
with sodium bisulfite using the EpiTect Bisulfite Kit, according
to the manufacturer’s protocol (Qiagen, Valencia, CA). Briefly,
2 μg of genomic DNA was treated with sodium bisulfite. Bisulfite-
treated DNA was bound to the membrane of an EpiTect spin
column, washed, desulfonated, washed, and eluted. JumpStart
Taq DNA polymerase (Sigma, St. Louis, MO) along with PCR
primers compatible with sodium bisulfite-converted sequence for
AARS exon 7: (Fwd [5′-AAGTTTGTTTTTTAAAGGGTTGTTTT-
3′] and Rev [5′-CCATCAACCAATACCACAATAATAAT-3′]), AARS
exon 8: (Fwd [5′-TTAAGATAAAATTTTTAGTTGGGAA-3′] and
Rev [5′-AAAAATAAACCTACCAAAAACTAAAC-3′]), AARS exon
9: (Fwd [5′-TGAAGAAGGATTTAGATATGGTGAAG-3′] and Rev
[5′-AAAAACATAAAAACCCACAATCAAT-3′]), and a region at
SOX3: (Fwd: [5′-AGGGAGTATTTATTTTTTTTGAGTAG-3′] and
Rev [5′-AAAAACCCCAAAATACACAATTCTA-3′]) were used to
amplify a 162 bp product encompassing AARS exon 7, a 177 bp
product encompassing AARS exon 8, a 230 bp product encompass-
ing AARS exon 9, and a 197 bp product amplifying a CpG island
in SOX3. The PCR products were electrophoresed through a 1%
agarose gel strained with ethidium bromide. Subsequently, PCR
products were excised from the gel and DNA was isolated using
the QIAquick Gel Extraction Kit (Qiagen) according to the man-
ufacturer’s protocol. Amplicons were cloned into the pCR4-TOPO
TA vector using the TOPO TA Cloning Kit for Sequencing (In-
vitrogen). Twenty resulting clones from each control DNA sample
were selected for sequencing at each locus. Bisulfite sequencing data
were analyzed using Sequencher DNA Sequence Assembly software
(Gene Codes, Ann Arbor, MI) and BiQ Analyzer software [Bock
et al., 2005].
Table 1. Identification of AARS Variants in Patients with CMT
cDNA changea
Amino acid
changeb
dbSNP
accession no.
NINDS control
chromosomes
ClinSeqTM
chromosomes
c.986G>A R329H NP 0/1,086 0/802
c.1685C>T T562I NP 8/1,088 4/802
c.2185C>T R729W NP 2/1,090 1/788
c.2333A>C E778A NP 0/954 0/802
c.2791G>A G931S NP 11/1,106 12/802
c.2900A>T K967M rs35744709 ND 12/752
aNucleotide positions are relative to the open reading frame from GenBank Accession
No. NM_001605.2. Nucleotide numbering reflects cDNA numbering with +1
corresponding to the A of the ATG translation initiation codon in the reference
sequence, according to journal guidelines.
bAmino acid positions are relative to GenBank Accession No. NP_001596.2. The
initiation codon is codon 1.
NP, not present; ND, not done.
Results
Identification of AARS Variants
To further evaluate the role of AARS mutations in CMT dis-
ease, we performed PCR-based DNA sequencing analysis of each
AARS coding exon in DNA samples isolated from 363 patients
with CMT and no known disease-causing mutation. This investi-
gation revealed six missense AARS variants: p.Arg329His (R329H),
p.Thr562Ile (T562I), p.Arg729Trp (R729W), p.Glu778Ala (E778A),
p.Gly931Ser (G931S), and p.Lys967Met (K967M) (Table 1). To de-
termine the frequency of each variant, we genotyped DNA samples
isolated from neurologically unaffected individuals of European
decent (NINDS/Coriell). The R329H and E778A AARS variants
were not identified in 1,086 and 954 chromosomes tested, respec-
tively. Neither variant was detected in 802 chromosomes tested from
the ClinSeqTM cohort [Biesecker et al., 2009]. Conversely, T562I,
R729W, and G931S AARS were detected in eight of 1,088 (fre-
quency = 0.0073), two of 1,090 (frequency = 0.0018), and 11 of 1,106
chromosomes (frequency = 0.0099), respectively (Table 1). The
K967M variant is present in dbSNP (rs35744709). Each of theAARS
variants found in the neurologically normal controls was also iden-
tified in the ClinSeqTM cohort (Table 1) [Biesecker et al., 2009]. To-
gether, these data indicate that R329H and E778A are not common
polymorphisms.
The R329Hvariant (c.986G>A)was identified in family CMT243,
a large Australian kindred including nine individuals affected with
CMTdisease (Fig. 1A and Supp. Fig. S1). Affected individuals exhib-
ited early-onset axonal neuropathywith variable sensorineural deaf-
ness. Progressive gait difficulty, foot drop, pes cavus, and hammer
toes were also reported. Nerve conduction velocities were within the
intermediate range and audiology showed mild to moderate high-
frequency sensory neural loss. Importantly, samples from affected
individuals in CMT243 were negative for mutations in other genes
previously implicated in CMT disease, including PMP22 (MIM#
601097), MFN2 (MIM# 608507), GDAP1 (MIM# 606598), and
EGR2 (MIM# 129010).
The E778A variant (c.2333 A>C) was identified in CMT513, an
Australian family that includes a proband with sporadic axonal
CMT, rippling muscles, and cramps, and three additional individ-
uals affected only with rippling muscles and cramps (Fig. 1A and
Supp. Fig. S1). Affected individuals exhibited cramps at night with
rippling and twitching muscles at rest. Conduction studies in the
proband (Fig. 1A; arrow) showed a motor and sensory axonal neu-
ropathy.Clinical examination revealed absent reflexes,wastingof the
feet, and mild distal sensory loss in the lower limbs. DNA samples
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Figure 1. Segregation, localization, and conservation of AARS variants. A: Genotyping was performed to determine the segregation of AARS
variants with disease in families with CMT. Filled symbols represent affected individuals, with black indicating a diagnosis of CMT, and red
indicating a diagnosis of rippling muscles and cramps. Empty symbols indicate unaffected individuals. Where applicable, the individual’s genotype
is indicatedwith the amino acid change or + (for a wild-type allele). Slashes indicate deceased individuals, the question mark indicates an unknown
diagnosis, and the arrow indicates the proband in family CMT513. All individuals have been designated with a diamond symbol to protect identities.
B: Each variant was mapped to the known functional domains of the AARS protein indicated in red (catalytic domain), green (tRNAAla binding
domain), and orange (editing domain). The position of each domain along the protein is indicated below the cartoon. C: Multiple-species protein
alignments were generated to assess the conservation of each affected amino acid position. For each of the three detected variants, the affected
amino acid is shown along with the flanking AARS protein sequence in multiple, evolutionarily diverse species (indicated on the left). Note that
each specific amino acid change is given at the top, with conservation indicated in red for each protein sequence.
from affected individuals from family CMT513 tested negative for
PMP22 genemutations. Furthermore, the proband from this family
tested negative for mutations in CAV3 (MIM# 601253), which is
commonly mutated in patients with rippling muscle disease [Betz
et al., 2001].
In addition to the above-mentionedvariants, a thirdAARSvariant
(p.Asn71Tyr [N71Y]) was recently identified in a Taiwanese family
with axonal CMT disease [Lee et al., 2011]. Thus, we also included
N71Y AARS in our functional analyses (see below).
N71Y and R329H AARS Affect Highly Conserved Amino
Acid Residues
To determine if the identified AARS variants reside at amino acid
residues important for enzyme function, we mapped each affected
AARS residue onto the protein. Asparagine 71 is located within
the catalytic domain of the enzyme, arginine 329 resides within
the tRNA-binding domain, and glutamic acid 778 is located in the
editing domain of the protein, which ensures the fidelity of tRNAALA
charging (Fig. 1B). The evolutionary conservation of each affected
AARS residuewas assessed by aligningAARSprotein orthologs from
multiple species. Asparagine 71 is conserved among all eight species
analyzed with the exception of bacteria (Fig. 1C). Arginine 329 is
conserved in all eight species analyzed, including yeast and bacteria
(Fig. 1C). In contrast, glutamic acid 778 is not conserved among
vertebrate species; note that an alanine is permissive in the zebrafish
ortholog of AARS (Fig. 1C). Thus, the N71Y and R329HAARS vari-
ants alter amino acid residues that are conserved between humans
and single-celled organisms, and that reside within critical func-
tional domains, suggesting that these variants may impair enzyme
function.
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Table 2. Aminoacylation Kinetics of AARS Protein Variants
Km (mM) kcat (s
–1) kcat/Km (mM
–1s–1) Ratio to WT
Wild-type 0.70 ± 0.21 0.54 ± 0.04 0.81 ± 0.19 1
N71Y 2.9 ± 0.7 0.0006 ± 0.0004 0.0002 ± 0.0001 1/4,130
R329H 3.0 ± 0.2 0.047 ± 0.0001 0.016 ± 0.001 1/50
E778A 0.89 ± 0.08 0.53 ± 0.001 0.60 ± 0.05 1/1.4
N71Y and R329H AARS Display Impaired Enzyme
Activity In Vitro
AARS catalyzes the aminoacylation of tRNAAla in the cytoplasm
via a two-step aminoacylation reaction [Antonellis and Green,
2008]. Previous aminoacylation analyses performed using disease-
associated GARS, YARS, and KARSmutations showed that the ma-
jority show impaired aminoacylation activity [Cader et al., 2007;
Jordanova et al., 2006; McLaughlin et al., 2010; Nangle et al., 2007;
Storkebaum et al., 2009; Xie et al., 2007]. However, the AARSmuta-
tionsdescribedabovehavenotbeen tested for aneffect onaminoacy-
lation activity. We therefore tested the ability of each human AARS
protein variant to catalyze aminoacylation in vitro. Human cyto-
plasmic tRNAAla was synthesized via in vitro transcription and used
as a substrate for aminoacylation in the presence of tritium-labeled
alanine. Analyses of the catalytic efficiency (kcat/Km) of aminoacyla-
tion showed that N71Y and R329HAARS severely impaired enzyme
activity, resulting in a 4,130-fold and 50-fold decrease in catalytic
efficiency compared to wild-type AARS, respectively (Fig. 2A and
Table 2). In contrast, E778A AARS showed catalytic activity similar
to the wild-type enzyme (Fig. 2A), and the nonpathogenic T562I
AARS enzyme that results from an AARS polymorphism was not
associated with decreased enzyme activity (data not shown). In ad-
dition, analysis of the editing activity of E778A AARS showed that
this variant enzyme had similar editing activity as the wild-type
enzyme (Supp. Fig. S2). Thus, the N71Y and R329H AARS alleles
encode enzyme subunits with severely reduced charging capacity
in vitro.
N71Y and R329H AARS Do Not Complement Deletion
of the Yeast Ortholog
Many disease-associated GARS, YARS, and KARS mutations are
unable to complement deletionof the corresponding yeast orthologs
[Antonellis et al., 2006; Jordanova et al., 2006; McLaughlin et al.,
2010]. To further assess for mutation-associated defects in AARS
enzyme function, we modeled each AARS variant in the yeast (S.
cerevisiae) ortholog ALA1 (Table 3) and determined the ability of
each variant to complement the deletion of ALA1 compared to the
wild-type yeast gene. A haploid yeast strain with endogenous ALA1
deleted (ala1) was maintained via transformation of a wild-type
copy of ALA1 on a URA3-bearing plasmid (pRS316). Experimental
(wild-type and mutant) ALA1 alleles were generated on a LEU2-
bearing vector (pRS315) and transformed into the strain described
above. Viability was evaluated by analysis of growth on solid me-
dia containing 5-FOA. Two experimental vectors were prepared for
each mutant and five colonies from each transfection assay were
evaluated. An insert-free pRS315 construct was unable to rescue the
ala1 allele, whereas wild-type ALA1 was able to fully complement
the ala1 allele (Fig. 2B). These data are consistent with ALA1 be-
ing an essential gene, and the wild-type experimental ALA1 vector
harboring a functional allele, respectively. The E778A ALA1 allele
allowed growth in a manner consistent with wild-type ALA1. In
contrast, N71Y and R329H ALA1 were unable to rescue the ala1
Figure 2. Functional characterization of AARS variants. A: Aminoa-
cylation of tRNAAla with alanine by AARS enzymes. Analysis of the rate
of aminoacylation (pmole/min/pmole of enzyme) as a function of tRNA
concentration for the wild-type AARS enzyme (red) and the mutants
N71Y (blue), and R329H (green), and E778A (black) after fitting the data
to the Michaelis–Menten equation. Values represent the average of
two independent experiments, and error bars indicate the standard de-
viation. B: Five representative cultures of each yeast strain (indicated
along the top of the panel) were inoculated and grown on solid growth
mediumcontaining 5-FOA. Each strainwaspreviously transfectedwith a
vector containing no insert (pRS315 Empty), wild-type ALA1 (Wt ALA1),
or the indicated mutant form of ALA1 that modeled a human AARS
mutation (see Table 3). Two independently generated mutant-bearing
constructs were analyzed (indicated as “A” and “B” on the left side of
the panel). Before inoculating on 5-FOA-containing medium, each strain
was resuspended in 100 μl water, then diluted 1:10.
Table 3. Human AARS Variants Modeled in the Yeast Ortholog
ALA1
Human AARSa Yeast ALA1b
N71Y N75Y
R329H R329H
E778A D771A
aAmino acid coordinates correspond to GenBank accession number NP_001596.2.
bAmino acid coordinates correspond to GenBank accession number NP_014980.1.
allele. Combined, these data indicate that N71Y and R329H AARS
enzymes have strongly reduced functional activity.
Disease-associatedYARS variants have adominant-negative effect
when modeled in the yeast ortholog TYS1 [Jordanova et al., 2006].
To test N71Y, R329H, and E778A ALA1 for a dominant-negative
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effect, we performed growth curve analysis on the haploid yeast
strains (described above) before selection on 5-FOA (i.e., strains
that harbor two ALA1 expression constructs: two wild-type, or one
wild-type and onemutant). Similar experimentswere performed on
strains expressing eachmutantALA1 variant froma strongpromoter
(ADH1). In both experiments, no differences were seen in growth
patterns between strains expressing a mutant ALA1 variant and
those expressingwild-typeALA1 (datanot shown).Therefore,AARS
mutations do not appear to exert a dominant-negative effect when
modeled in yeast.
E778A AARS Does Not Mislocalize In Vitro
Several mutant GARS and YARS proteins have been shown to
mislocalize in vitro [Antonellis et al., 2006; Jordanova et al., 2006].
Because the E778A variant does not impair AARS function in ei-
ther aminoacylation or yeast viability assays, we sought to deter-
mine if the E778A AARS protein is mislocalized in neurons. We
first examined the endogenous localization of the AARS protein in
the mouse motor neuron cell line MN-1, after differentiation and
staining against anti-AARS [Salazar-Grueso et al., 1991]. Confocal
microscopy revealed diffuse localization throughout the cell and nu-
cleus, extending into the neurite projections (Supp. Fig. S3A and B).
Notably, this localization pattern is in contrast to the distinct granu-
lar staining of the endogenous GARS and YARS proteins [Antonellis
et al., 2006; Jordanova et al., 2006]. Subsequently, we assessed the
localization of E778A AARS by transfecting constructs expressing
either wild-type or E778A AARS C-terminally tagged with DsRed
in MN-1 cells and examining the localization pattern after differ-
entiation. Similar to wild-type AARS, E778A AARS was localized
diffusely throughout the cell and neurite projections (Supp. Fig. S3C
and D; arrows). These data indicate that E778A AARS is not grossly
mislocalized in neurons at the resolution of confocal microscopy.
R329H AARS is a Recurrent Mutation
The R329H AARS variant has now been identified in three fam-
ilies with CMT disease from different world populations ([Latour
et al., 2010] and current study). Todetermine if theAustralian family
described herein shares a haplotypewith either of the two previously
reported French families, we performed haplotype analysis on indi-
viduals from familyCMT243. These studies revealed that theR329H
AARS mutation resides on three distinct haplotypes in each of the
three families (Fig. 3A), consistent with this variant representing a
recurrent mutation.
To assess themechanism of the recurrent R329HAARSmutation,
we examined theDNA sequence surrounding the c.986G>A change.
Interestingly, when the protein-coding DNA sequence is observed
in the reverse-complemented state, the affected nucleotide (c.986G)
is a cytosine within a CpG dinucleotide (Fig. 3B). It is estimated
that approximately 80% of CpG cytosines are methylated to form
5-methylcytosine (5mC) in human cells [Ehrlich et al., 1982]. Im-
portantly, 5mCs are known to be mutational “hotspots” [Cooper
and Youssoufian, 1988; Coulondre et al., 1978] that arise due to
spontaneous deamination of the 5mC to form thymine [Selker and
Stevens, 1985], and if this event were to occur at the CpG dinu-
cleotide indicated in Figure 3B, this would result in the c.986 G>A
change on the opposite coding strand of AARS exon 8. To address
this possibility, we evaluated the CpG dinucleotide content of the
AARS locus using EMBOSS CpG Plot (Fig. 3C) [Rice et al., 2000].
Interestingly, in contrast to the remaining AARS coding exons, the
exon encoding R329 (exon 8) has a high CpG dinucleotide content
(6.48%; Fig. 3C).
Table 4. Predicted Consequences for Deaminated Methyl-CpGs
in AARS Exon 8
CpGa Affected amino acid Predicted change
1b R326 W
1c R326 Q
2b R329 C
2c R329 H
3b R330 ∗
3c R330 Q
4b R333 ∗
4c R333 Q
5c A335 T
6b T348 M
7c V354 I
aNumbers refer to the annotations presented in Figure 3E.
bCpG on coding strand.
cCpG on noncoding strand.
∗Indicates a stop codon.
SodiumbisulfiteDNA sequencing is a common approach to iden-
tify 5mCs in genomicDNA.Todetermine if theR329HAARS variant
might be generated via methylation-mediated deamination of the
identified CpG dinucleotide, we PCR-amplified a genomic region
surroundingAARS exon 8 from two independent humanDNA sam-
ples treated with sodium bisulfite. Subsequently, each DNA sample
was subjected to subcloning, and 18 clones from each sample were
selected for DNA sequence analysis. Visual examination of the DNA
sequencing data showed that >99% of non-CpG cytosines (Fig. 3D,
black arrows)were converted to thymidine. In contrast, cytosines re-
siding in CpGdinucleotides were largely unconverted and remained
cytosines (Fig. 3D, red arrows). To predict the methylation status of
each cytosine in AARS exon 8, the sequence data from each clone
were analyzedwith BiQAnalyzer software [Bock et al., 2005]. A total
of 28 cytosines were analyzed, including seven cytosines residing in
CpG dinucleotides. In 94% of the clones examined, all seven CpG
cytosinesweremethylated, including themutated cytosine that gives
rise to R329H AARS (Fig. 3E).
To ensure the validity of the above-mentioned data, we employed
the BiQ Analyzer software to assess similar DNA sequencing data
generated from PCR products encompassing AARS exon 7 and 9, as
well as a third, unlinked and previously characterized CpG island
at the X-linked SOX3 locus [Cotton et al., 2009]. More than 90% of
the CpGs in AARS exon 7 are methylated, 11% of CpGs in AARS
exon 9 are methylated (Supp. Fig. S4A and B), and the SOX3 locus
displayed the expected methylation patterns—DNA isolated from a
female individual contained higher levels of methylation than DNA
isolated from a male individual (Supp. Fig. S4C).
Finally, we predicted the consequences of deamination of each
5mCwithinAARS exon 8 to determine if C>T transitions could give
rise to additional pathogenic amino acid changes. Because the tran-
sition could occur on either stand, there are 14 possible deamination
consequences. Of these, 11 are predicted to affect the AARS amino
acid sequence, including two that would result in a stop codon
(Table 4). Combined, these data support the notion that R329H
AARS is a recurrent mutation generated via 5mC deamination of
a CpG dinucleotide on the noncoding DNA strand. Furthermore,
AARS exon 8 is predicted to be a highly mutable region with poten-
tially detrimental consequences, and should be closely scrutinized
for mutations in patients with dominant axonal CMT.
Discussion
Here, we present genetic and functional data showing that
R329H AARS is a recurrent, loss-of-function mutation that causes
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Figure 3. R329H AARS is a recurrent mutation. A: Haplotype analysis was performed along chromosome 16 in family CMT243 and compared
to the published data for the previously identified families with the R329H AARS mutation (Family 1 and Family 2). The three genotyped markers
and AARS locus are indicated on the left, along with the alleles identified on each disease-associated haplotype (in bps). The distance between
each locus is indicated in megabases (Mb). B: The codon affected by the R329H AARS variant harbors a CpG dinucleotide. A representative trace
(in the reverse-complement) of the region surrounding the R329H codon is shown. The CpG is indicated with a line and the affected cytosine is
indicated with an arrow. C: The AARS locus was computationally evaluated for CpG dinucleotide content (see methods). Each AARS exon number
is indicated along the top of the panel, with vertical white boxes representing coding exons and horizontal lines representing introns. Areas with
at least 100 bps containing an observed/expected CpG dinucleotide ratio > 60% and GC content > 50% are indicated in yellow. Note that AARS
exon 8 is the only coding region to meet these criteria. D: The methylation status of CpG dinucleotides in AARS exon 8 was evaluated via bisulfite
(NaHSO3) treated DNA sequencing analysis. The DNA sequence from 10 representative clones harboring AARS exon 8 after bisulfite treatment
are shown, with the genomic consensus sequence (“Genomic”) provide along the top. Converted cytosines are indicated with black arrows and
nonconverted cytosines are indicated with red arrows. Note that all non-CpG cytosines are converted to thymines, while all CpG cytosines remain
unchanged indicating that they are methylated. E: AARS exon 8 harbors multiple, methylated cytosines in CpG dinucleotides. A representation of
bisulfite sequencing products of the seven CpGs (indicated along the top of the panel) residing in AARS exon 8 is shown for two control individuals
(Control 1 and Control 2). Eighteen clones were analyzed for each control. Filled circles indicate methylated CpGs. The arrow indicates the affected
CpG giving rise to R329H AARS.
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dominant axonal CMT disease. In addition, we present functional
data indicating that the N71Y AARS variant also results in a loss
of AARS enzyme function; these data are consistent with this al-
lele being pathogenic in a Taiwanese family with dominant axonal
CMT disease [Lee et al., 2011]. Importantly, these data provide
key insight into the molecular pathology of CMT-related ARS gene
mutations. To date, four ARSs have been implicated in CMT dis-
ease characterized by an axonal pathology [Antonellis et al., 2003;
Jordanova et al., 2006; Latour et al., 2010; McLaughlin et al., 2010].
Each glycyl-tRNA synthetase (GARS) mutation tested causes im-
paired tRNA-charging capacity and/or mislocalization in neurons
compared to the wild-type enzyme [Antonellis et al., 2006; Cader
et al., 2007; Nangle et al., 2007; Xie et al., 2007]. Furthermore,
all three disease-associated tyrosyl-tRNA synthetase (YARS) muta-
tions impair the first or second step of the aminoacylation reaction,
and also affect the proper localization of YARS in cultured neurons
[Jordanova et al., 2006; Storkebaum et al., 2009]. Finally, two lysyl-
tRNA synthetase (KARS) mutations identified in a compound het-
erozygote patient with CMT disease result in a null allele and a hy-
pomorphic allele, which would dramatically reduce the production
of Lys-tRNALYS molecules [McLaughlin et al., 2010]. Importantly,
these loss-of-function characteristics have not been observed upon
analysis of nonpathogenic ARS variants (this study and reference
[McLaughlin et al., 2010]); however, additional ARS variants in
this class need to be evaluated. Combined with the R329H AARS
data presented here, these observations strongly suggest that there
is an impaired tRNA-charging component to the pathophysiology
of ARS-related CMT disease. One possibility is that the axonopathy
phenotype is causedby adominant-negative effect ofARSmutations
that greatly reduces (e.g., more than 50%) tRNA-charging capacity,
which is supported by findings that: (1) the majority of ARS-related
CMT phenotypes are dominant; (2) most ARS mutations are mis-
sense amino acid changes; (3) ARS enzymes implicated in CMT
to date act as oligomers; and (4) haploinsufficiency of Gars does
not cause axonopathy in a mouse model. However, a toxic gain-of-
function unrelated to tRNA charging cannot yet be ruled out and,
moving forward, it will be important to study GARS, YARS, KARS,
and AARS mutants to tease out the precise molecular pathology of
ARS-related CMT disease.
Our mutation screen of the AARS gene also identified the E778A
variant, which segregated with dominant rippling muscle disease
in a family that included a proband with the additional pheno-
type of axonal CMT disease. Although E778A was absent in over
950 chromosomes from neurologically normal control individu-
als, family CMT513 is too small for linkage analysis and we were
unable to identify any functional consequences of E778A AARS
in aminoacylation, yeast complementation, or protein localization
assays. However, this finding raises interesting questions about pos-
sible genotype/phenotype correlations associated with AARS mu-
tations. For example, homozygosity for an A734E mutation in the
editing domain of the mouse Aars gene causes ataxia and hair fol-
licle degeneration in the sti mouse [Lee et al., 2006]. Biochemical
analyses showed that the A734E AARS enzyme has tRNA-charging
activity consistent with wild-type AARS, however, the editing ca-
pacity of the enzyme was decreased [Lee et al., 2006]. The E778A
AARS variant described here resides within the editing domain of
the AARS enzyme, and while we were unable to detect an editing
defect associated with the E778A enzyme, it will be important to de-
termine if E778A AARS causes rippling muscle disease via another
pathogenic mechanism (e.g., using animal models). One possibility
is that E778A AARS affects some secondary, noncanonical function
of the AARS enzyme in neuronal ormuscle tissues. Indeed, ARSs are
known to possess a wide variety of noncanonical functions in hu-
mans including: HIV virion packaging, RNA biogenesis, apoptotic
inhibition, angiogenic signaling, and immune response stimulation
[Antonellis and Green, 2008]. However, at this point E778A AARS
should be considered a rare, non-pathogenic variant.
Our haplotype and bisulfite DNA sequence analyses indicate that
R329H AARS is a recurrent mutation and suggest that the preva-
lenceof thismutation inCMTdisease shouldbe further investigated.
Recurrent, methylation-mediated and disease-associatedmutations
have been described in other genes including TP53 (MIM# 191170),
PAH (MIM# 612349), and MECP2 (MIM# 300005) [Greenblatt
et al., 1994; Murphy et al., 2006; Wan et al., 1999]. These findings
often dictate mutation-specific screening of other, relevant patients
with no known mutation. We also discovered that six additional
CpGs in AARS exon 8 are methylated, suggesting that this exon
has the capacity to be highly mutable. Combined, these data have
important clinical implications. The recurrent nature of the R329H
AARSmutation, and the fact that the affected CpG is constitutively
methylated strongly suggest that all patients with axonal CMT dis-
ease and no known mutation should be screened for the R329H
AARSmutation. Furthermore, it may be prudent to thoroughly as-
sess each of the remaining methylated CpGs in AARS exon 8 in
similar patients to fully evaluate the AARS gene for CMT-associated
mutations.
The data presented here improve our understanding of the role
of AARS mutations in CMT disease. Specifically, they indicate that
AARS mutations may act via impaired enzyme function, that the
AARS locus should be assessed for mutations in patients with CMT
disease, and further support the notion that all 37 human genes
encoding an ARS can be considered candidate genes for neurode-
generative diseases.
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